Plain-English translation of NCT06905509 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it works better when given alongside standard chemotherapy drugs and a stem cell transplant procedure. The study focuses on people whose aggressive lymphoma has returned after treatment or never responded to their first round of therapy. Researchers want to understand whether adding this medication to the existing treatment plan can improve outcomes for these patients.
Large B-cell lymphomas that come back or don't respond to initial treatment are very difficult to manage and have poor survival rates. This trial exists to see if this medication can improve how well the standard chemotherapy and stem cell transplant procedure work for these hard-to-treat cases.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive injections of the medication twice weekly for three months while also receiving standard chemotherapy drugs. Then you would undergo a stem cell transplant procedure as part of your standard care. After the transplant, you would continue receiving the medication for up to a year, with the frequency decreasing over time. Throughout the study, you would have regular blood draws, imaging scans (CT or PET), and heart function tests, with follow-up visits continuing for 2 years after your transplant.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States